Neutralizing antibodies develop in some patients to varying degrees following infection with SARS-CoV-2 SARS-CoV-2 spike protein ligand binding assay allows rapid quantification of COIVD19 neutralizing antibodies in serum that block the interaction between the viral spike protein and its target the ACE2 receptor.